B. Riley Securities Reiterates Buy on Arrowhead Pharma, Maintains $55 Price Target
Portfolio Pulse from richadhand@benzinga.com
B. Riley Securities analyst Mayank Mamtani has reiterated a 'Buy' rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a price target of $55.
July 20, 2023 | 2:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arrowhead Pharma's stock rating has been reiterated as 'Buy' by B. Riley Securities with a maintained price target of $55.
The reiteration of a 'Buy' rating by a reputable analyst like Mayank Mamtani from B. Riley Securities is a positive signal for Arrowhead Pharma. The maintained price target of $55 indicates the analyst's confidence in the company's potential to reach this price, which could attract investors and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100